Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)

Alessia Finotti, Matteo Allegretti, Jessica Gasparello, Patrizio Giacomini, Demetrios A. Spandidos, Giuseppe Spoto, Roberto Gambari

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

In oncology, liquid biopsy is used in the detection of next-generation analytes, such as tumor cells, cell-free nucleic acids and exosomes in peripheral blood and other body fluids from cancer patients. It is considered one of the most advanced non-invasive diagnostic systems to enable clinically relevant actions and implement precision medicine. Medical actions include, but are not limited to, early diagnosis, staging, prognosis, anticipation (lead time) and the prediction of therapy responses, as well as follow-up. Historically, the applications of liquid biopsy in cancer have focused on circulating tumor cells (CTCs). More recently, this analysis has been extended to circulating free DNA (cfDNA) and microRNAs (miRNAs or miRs) associated with cancer, with potential applications for development into multi-marker diagnostic, prognostic and therapeutic signatures. Liquid biopsies avoid some key limitations of conventional tumor tissue biopsies, including invasive tumor sampling, under-representation of tumor heterogeneity and poor description of clonal evolution during metastatic dissemination, strongly reducing the need for multiple sampling. On the other hand, this approach suffers from important drawbacks, i.e., the fragmentation of cfDNA, the instability of RNA, the low concentrations of certain analytes in body fluids and the confounding presence of normal, as well as aberrant DNAs and RNAs. For these reasons, the analysis of cfDNA has been mostly focused on mutations arising in, and pathognomonicity of, tumor DNA, while the analysis of cfRNA has been mostly focused on miRNA patterns strongly associated with neoplastic transformation/progression. This review lists some major applicative areas, briefly addresses how technology is bypassing liquid biopsy limitations, and places a particular emphasis on novel, PCR-free platforms. The ongoing collaborative efforts of major international consortia are reviewed. In addition to basic and applied research, we will consider technological transfer, including patents, patent applications and available information on clinical trials aimed at verifying the potential of liquid biopsy in cancer.

Original languageEnglish
Pages (from-to)1395-1434
Number of pages40
JournalInternational Journal of Oncology
Volume53
Issue number4
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Biopsy
Polymerase Chain Reaction
Neoplasms
MicroRNAs
DNA
Body Fluids
Clonal Evolution
Exosomes
Circulating Neoplastic Cells
Precision Medicine
Patents
RNA Stability
Nucleic Acids
Early Diagnosis
Clinical Trials
RNA
Technology
Mutation
Therapeutics
Research

Keywords

  • Circulating free DNA
  • Circulating tumor cells
  • Liquid biopsy
  • MicroRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). / Finotti, Alessia; Allegretti, Matteo; Gasparello, Jessica; Giacomini, Patrizio; Spandidos, Demetrios A.; Spoto, Giuseppe; Gambari, Roberto.

In: International Journal of Oncology, Vol. 53, No. 4, 01.10.2018, p. 1395-1434.

Research output: Contribution to journalReview article

Finotti, Alessia ; Allegretti, Matteo ; Gasparello, Jessica ; Giacomini, Patrizio ; Spandidos, Demetrios A. ; Spoto, Giuseppe ; Gambari, Roberto. / Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). In: International Journal of Oncology. 2018 ; Vol. 53, No. 4. pp. 1395-1434.
@article{f9116718e95f4678823e80fbc8ec538e,
title = "Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)",
abstract = "In oncology, liquid biopsy is used in the detection of next-generation analytes, such as tumor cells, cell-free nucleic acids and exosomes in peripheral blood and other body fluids from cancer patients. It is considered one of the most advanced non-invasive diagnostic systems to enable clinically relevant actions and implement precision medicine. Medical actions include, but are not limited to, early diagnosis, staging, prognosis, anticipation (lead time) and the prediction of therapy responses, as well as follow-up. Historically, the applications of liquid biopsy in cancer have focused on circulating tumor cells (CTCs). More recently, this analysis has been extended to circulating free DNA (cfDNA) and microRNAs (miRNAs or miRs) associated with cancer, with potential applications for development into multi-marker diagnostic, prognostic and therapeutic signatures. Liquid biopsies avoid some key limitations of conventional tumor tissue biopsies, including invasive tumor sampling, under-representation of tumor heterogeneity and poor description of clonal evolution during metastatic dissemination, strongly reducing the need for multiple sampling. On the other hand, this approach suffers from important drawbacks, i.e., the fragmentation of cfDNA, the instability of RNA, the low concentrations of certain analytes in body fluids and the confounding presence of normal, as well as aberrant DNAs and RNAs. For these reasons, the analysis of cfDNA has been mostly focused on mutations arising in, and pathognomonicity of, tumor DNA, while the analysis of cfRNA has been mostly focused on miRNA patterns strongly associated with neoplastic transformation/progression. This review lists some major applicative areas, briefly addresses how technology is bypassing liquid biopsy limitations, and places a particular emphasis on novel, PCR-free platforms. The ongoing collaborative efforts of major international consortia are reviewed. In addition to basic and applied research, we will consider technological transfer, including patents, patent applications and available information on clinical trials aimed at verifying the potential of liquid biopsy in cancer.",
keywords = "Circulating free DNA, Circulating tumor cells, Liquid biopsy, MicroRNA",
author = "Alessia Finotti and Matteo Allegretti and Jessica Gasparello and Patrizio Giacomini and Spandidos, {Demetrios A.} and Giuseppe Spoto and Roberto Gambari",
year = "2018",
month = "10",
day = "1",
doi = "10.3892/ijo.2018.4516",
language = "English",
volume = "53",
pages = "1395--1434",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)

AU - Finotti, Alessia

AU - Allegretti, Matteo

AU - Gasparello, Jessica

AU - Giacomini, Patrizio

AU - Spandidos, Demetrios A.

AU - Spoto, Giuseppe

AU - Gambari, Roberto

PY - 2018/10/1

Y1 - 2018/10/1

N2 - In oncology, liquid biopsy is used in the detection of next-generation analytes, such as tumor cells, cell-free nucleic acids and exosomes in peripheral blood and other body fluids from cancer patients. It is considered one of the most advanced non-invasive diagnostic systems to enable clinically relevant actions and implement precision medicine. Medical actions include, but are not limited to, early diagnosis, staging, prognosis, anticipation (lead time) and the prediction of therapy responses, as well as follow-up. Historically, the applications of liquid biopsy in cancer have focused on circulating tumor cells (CTCs). More recently, this analysis has been extended to circulating free DNA (cfDNA) and microRNAs (miRNAs or miRs) associated with cancer, with potential applications for development into multi-marker diagnostic, prognostic and therapeutic signatures. Liquid biopsies avoid some key limitations of conventional tumor tissue biopsies, including invasive tumor sampling, under-representation of tumor heterogeneity and poor description of clonal evolution during metastatic dissemination, strongly reducing the need for multiple sampling. On the other hand, this approach suffers from important drawbacks, i.e., the fragmentation of cfDNA, the instability of RNA, the low concentrations of certain analytes in body fluids and the confounding presence of normal, as well as aberrant DNAs and RNAs. For these reasons, the analysis of cfDNA has been mostly focused on mutations arising in, and pathognomonicity of, tumor DNA, while the analysis of cfRNA has been mostly focused on miRNA patterns strongly associated with neoplastic transformation/progression. This review lists some major applicative areas, briefly addresses how technology is bypassing liquid biopsy limitations, and places a particular emphasis on novel, PCR-free platforms. The ongoing collaborative efforts of major international consortia are reviewed. In addition to basic and applied research, we will consider technological transfer, including patents, patent applications and available information on clinical trials aimed at verifying the potential of liquid biopsy in cancer.

AB - In oncology, liquid biopsy is used in the detection of next-generation analytes, such as tumor cells, cell-free nucleic acids and exosomes in peripheral blood and other body fluids from cancer patients. It is considered one of the most advanced non-invasive diagnostic systems to enable clinically relevant actions and implement precision medicine. Medical actions include, but are not limited to, early diagnosis, staging, prognosis, anticipation (lead time) and the prediction of therapy responses, as well as follow-up. Historically, the applications of liquid biopsy in cancer have focused on circulating tumor cells (CTCs). More recently, this analysis has been extended to circulating free DNA (cfDNA) and microRNAs (miRNAs or miRs) associated with cancer, with potential applications for development into multi-marker diagnostic, prognostic and therapeutic signatures. Liquid biopsies avoid some key limitations of conventional tumor tissue biopsies, including invasive tumor sampling, under-representation of tumor heterogeneity and poor description of clonal evolution during metastatic dissemination, strongly reducing the need for multiple sampling. On the other hand, this approach suffers from important drawbacks, i.e., the fragmentation of cfDNA, the instability of RNA, the low concentrations of certain analytes in body fluids and the confounding presence of normal, as well as aberrant DNAs and RNAs. For these reasons, the analysis of cfDNA has been mostly focused on mutations arising in, and pathognomonicity of, tumor DNA, while the analysis of cfRNA has been mostly focused on miRNA patterns strongly associated with neoplastic transformation/progression. This review lists some major applicative areas, briefly addresses how technology is bypassing liquid biopsy limitations, and places a particular emphasis on novel, PCR-free platforms. The ongoing collaborative efforts of major international consortia are reviewed. In addition to basic and applied research, we will consider technological transfer, including patents, patent applications and available information on clinical trials aimed at verifying the potential of liquid biopsy in cancer.

KW - Circulating free DNA

KW - Circulating tumor cells

KW - Liquid biopsy

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=85052282271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052282271&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4516

DO - 10.3892/ijo.2018.4516

M3 - Review article

C2 - 30085333

AN - SCOPUS:85052282271

VL - 53

SP - 1395

EP - 1434

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -